US clinical-stage biotech Vigil Neuroscience (Nasdaq: VIGL) today announced a disappointing update on the Phase II IGNITE ...

Vigil on Wednesday said it is ending a Phase 2 study of iluzanebart in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, or ALSP, after the drug showed no ...

Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of ...

蛇咬伤后常出现神经毒性表现，为明确儿科患者蛇咬伤后是否存在特殊神经并发症，研究人员对相关病例开展研究。发现 1 例 3 岁患儿蛇咬伤后经 ASV 治疗仍出现癫痫等症状，MRI 显示多灶性白质病变，提示临床需关注蛇咬伤诱导的白质脑病。